Douglas Clark, Executive Director of the Patented Medicine Prices Review Board (PMPRB), Canada’s federal price regulator for patented medicines, highlights the PMPRB’s mandate to protect consumers against excessive prices for patented drugs, the rationale behind the recent proposed changes to their guidelines, and the role PMPRB can play within Canada’s regulatory landscape.
Doug, the Patented Medicine Prices Review Board (PMPRB) was established within a particular historical context to act as a sort of price regulator. Could you provide an introduction to PMPRB’s mandate?
"While our powers have changed a bit since 1987, our mandate is the same: to protect Canadian consumers from excessively-priced patented medicines, as well as to report on pharmaceutical trends and industry R&D."
